Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the transcript of Investors Conference Call for Un-audited financial results for the quarter and half-year September 30, 2022 conducted after the meeting of Board of Directors held on Thursday, October 20, 2022. Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated October 20, 2022, we enclose copies of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022 published on October 21, 2022 in MINT (English) and HINDUSTAN (Hindi). Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jubilant Ingrevia Limited has informed the Exchange about Audio recording of Investors Conference Call held on October 20, 2022. Q2FY23 Quarterly Result Announced for Jubilant Ingrevia Ltd.
Specialty Chemical firm Jubilant Ingrevia announced Q2FY23 results: Q2FY23 Consolidated: Overall Revenue grew by 7% on YoY basis, led by higher sales performance of Speciality Chemical Business. Speciality Chemicals revenue grew by 63% YoY driven by volume growth across product segments Nutrition and Health Solutions business continued to witness lower demand owing to post flu impact and excess inventory situation across the value chain, coupled with short term demand impact in Europe due to on-going geo-political situation. Chemical Intermediates volume have grown while revenue is lower, mainly impacted on account of lower prices of key RM i.e. Acetic Acid. EBITDA is at Rs. 160 Crore. Higher input cost due to non-availability of contracted Coal, coupled with lower volumes offtake of Vitamin B3 has impacted EBIDTA, though Specialty Chemical and Chemical Intermediate volumes have grown significantly. Lower EBITDA also resulted into lower profit after tax. ROCE for the quarter stood at 18.9% as against 27.8% in FY22 on TTM Basis ROE during the quarter stood at 14.5% as against 21.9% in ’FY22 on TTM basis H1FY23 Consolidated: Overall Revenue grew by 4% on YoY basis, mainly due to higher sales performance by Speciality Chemical Business. Speciality Chemicals revenue grew by 44% YoY driven by volume growth across product segments Nutrition and Health Solutions business performance was impacted mainly due to impact of Bird & Swine Flu in EU & US region and overall excess inventory situation across the value chain, coupled with short term demand impact in Europe due to on-going geo-political situation. Chemical Intermediates volume have grown while revenue is impacted mainly due to lower prices of key RM i.e. Acetic Acid. EBITDA at Rs. 311 Crore. The EBITDA is impacted due to Chemical Intermediate segments EBITDA normalization, lower volumes offtake of Vitamin B3 and higher input costs impact in Speciality chemical business due to non-availability of contracted coal. Lower EBITDA also resulted into lower profit after tax. ROCE for the period stood at 18.9% as against 27.8% in FY22 on TTM Basis ROE during the period stood at 14.5% as against 21.9% in ’FY22 on TTM basis Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co Chairman, Jubilant Ingrevia Limited said: “We are pleased to announce stable operational and financial performance during the quarter under review, despite continuing headwinds on account of higher energy costs during the current financial Year. Our Specialty Chemicals Business revenue grew by 63% YoY, on account of better demand across all products within the segment. Margins are impacted mainly on account of higher cost of energy due to restriction on contracted coal supplies. While we expect the coal supply to normalize soon, we also continue to explore alternate energy solutions for future. In Nutrition & Health Solution business flu situation in US and Europe is normalizing, however demand of Vitamin B3 continue to be suppressed owing to post flu impact and excess inventory across the value chain. Our focus on niche segments like Food & Cosmetics is showing positive results and we continue to increase our revenue share in this segment. We also believe that the demand challenges of Vitamin B3 are short term. We continue to improve market share in our Animal nutrition business of Vitamin B4 and other Branded Premix products. Our Chemical Intermediates Business continue to witness strong demand resulting in volume growth. Business continues to improve its leadership position in Acetic Anhydride in domestic and international market. Revenue impact on YoY basis was primarily driven by lower prices of feed stock leading to lower sales prices of Ethyl Acetate and Acetic Anhydride. We believe Jubilant Ingrevia Limited is well-positioned to deliver robust growth in the future backed by its comprehensive growth plan for its growth projects. The performance in the coming quarters will be driven by higher share from Specialty Chemicals where Company is scaling its capacity and capability, Nutrition and Health Solutions where the Company is enhancing its value-added range of products and in Chemical Intermediates segment where our core emphasis is on enhancing healthy volume contributions”. Result PDF Jubilant Ingrevia Ltd - 543271 - Unaudited Financial Results For Period Ended September 30, 2022
Unaudited Financial Results for period ended September 30, 2022 Jubilant Ingrevia Ltd - 543271 - Board Meeting Outcome for Submission Of Unaudited Financial Results For Period Ended September 30, 2022
Submission of unaudited financial results for period ended September 30, 2022 Jubilant Ingrevia Ltd - 543271 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing Confirmation Certificate for the quarter ended September 30, 2022 received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company. Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Company is organising a Conference Call on October 20, 2022 after submission of the financial results for the quarter and half-year ended September 30, 2022 to the Stock Exchanges. Details of the Conference Call are attached in the Intimation Letter. Jubilant Ingrevia Ltd - 543271 - Board Meeting Intimation for Considering Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half-Year Ended September 30, 2022.
Jubilant Ingrevia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2022 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022. Jubilant Ingrevia Ltd - 543271 - Announcement under Regulation 30 (LODR)-Issue of Securities
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 100 Crore on October 12, 2022.